A Pew study recommends legislative fixes to reduce risks of counterfeit, adulterated and substandard pharmaceuticals. According to a new white paper by the Pew Health Group, Americans’ medicines are increasingly manufactured in developing countries, where oversight is lower than in the U.S.
The U.S. Food and Drug Administration (FDA) estimates 40 percent of finished drugs and 80 percent of active ingredients and bulk chemicals used in U.S. drugs come from overseas, says Pew.[ Also Read: What Has President Obama Done About AIDS? ]
The white paper, After Heparin: Protecting Consumers from the Risks of Substandard and Counterfeit Drugs, finds that increased outsourcing of manufacturing, a complex and globalized supply chain and criminal actors create the potential for counterfeit or substandard medicines to enter the supply chain and reach patients.
For economic reasons, the migration of manufacturing abroad is likely to continue. At the same time, industry and government agencies have failed to adapt to the changing environment.[ Also Read: IBM Study on Connected Health Devices ]
“Today’s prescriptions are being produced under last century’s oversight,” said Allan Coukell, director of medical programs at the Pew Health Group.
Substandard or adulterated pharmaceutical materials from abroad have entered the U.S. on multiple occasions. In addition, the risks of domestic counterfeiting and diversion of stolen drugs are well documented.
The white paper, according to Pew, presents several case studies, including incidents involving heparin, a blood thinner adulterated during its manufacture in China, counterfeit vials of the anemia drug Epogen and stolen vials of insulin to illustrate the threats and suggest solutions.[ Also Read: Medicines for Diseases that Strike Women ]
After Heparin is based on public information, including FDA documents, U.S. Government Accountability Office (GAO) reports, congressional testimony, peer-reviewed journals and interviews with more than 50 supply chain experts and stakeholders.
The findings and recommendations were discussed during a recent two-day convening on the white paper that included a diverse group of industry representatives, ranging from ingredient manufacturers to community pharmacists.
The Pew Health Group is the health and consumer-product safety arm of The Pew Charitable Trusts, a nonprofit organization.